Company Analysis
Sign in

Gilead Sciences, Inc. (GILD)

Nasdaq: GILD · Biological Products, (No Diagnostic Substances) · Foster City, CA · filing with the SEC since 1994
Full chart Alerts Compare
Grade6.8
◀ Past 7.3● Present 7.5▶ Future 5.3
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

1,681 patents granted to the 34 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Gilead Sciences, Inc.’s names, not what it holds today.

Patents granted
1,681
1,647 utility, 24 design, 10 reissue, 1976 to Dec 31, 2025
Granted in 2025
74
Against 89 in 2024 and 84 in 2023
Applications published
2,179
139 of them in 2025
Names they are printed under
34
its own name, a subsidiary
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals172
Organic fine chemistry136
Biotechnology30
Medical technology6
Analysis of biological materials2
Measurement1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name34 counted
Gilead Sciences, Inc. its own name
US, as the owner printed on each patent. 1 more under the same name are not counted (printed in CA)
927 granted
406 published
Gilead Sciences, Inc. its own name
named as the applicant on its applications, in US
0 granted
810 published
IMMUNOMEDICS, INC. a subsidiary
US, as the owner printed on each patent
411 granted
276 published
Immunomedics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
184 published
IBC Pharmaceuticals, Inc. a subsidiary
US, as the owner printed on each patent
70 granted
44 published
Kite Pharma, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
108 published
Gilead Pharmasset LLC a subsidiary
US, as the owner printed on each patent
79 granted
22 published
CymaBay Therapeutics, Inc. a subsidiary
US, as the owner printed on each patent
43 granted
40 published
Kite Pharma, Inc. a subsidiary
US, as the owner printed on each patent
42 granted
22 published
Gilead Pharmasset LLC a subsidiary
named as the applicant on its applications, in US
0 granted
63 published
GILEAD CONNECTICUT, INC. a subsidiary
US, as the owner printed on each patent
30 granted
16 published
IBC Pharmaceuticals, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
39 published
Gilead Calistoga LLC a subsidiary
US, as the owner printed on each patent. 1 more under the same name are not counted (printed in CA)
16 granted
12 published
Forty Seven, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
24 published
Xinthera, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
18 published
YM BIOSCIENCES AUSTRALIA PTY LTD. a subsidiary
AU, as the owner printed on each patent. 10 more under the same name are not counted (printed in US, printed in CA)
13 granted
5 published
Forty Seven, LLC a subsidiary
US, as the owner printed on each patent
15 granted
2 published
Gilead Apollo, LLC a subsidiary
US, as the owner printed on each patent
16 granted
1 published
Gilead Apollo, LLC a subsidiary
named as the applicant on its applications, in US. 1 more under the same name are not counted (printed in CA)
0 granted
17 published
GILEAD CALISTOGA LLC a subsidiary
named as the applicant on its applications, in US
0 granted
16 published
Gilead Connecticut, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
16 published
XinThera, Inc. a subsidiary
US, as the owner printed on each patent
11 granted
0 published
CymaBay Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
10 published
Interius BioTherapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
9 published
MYR GMBH a subsidiary
DE, as the owner printed on each patent
1 granted
4 published
Interius Biotherapeutics, Inc. a subsidiary
US, as the owner printed on each patent
4 granted
0 published
MiroBio Limited a subsidiary
named as the applicant on its applications, in GB
0 granted
4 published
Tmunity Therapeutics Inc. a subsidiary
US, as the owner printed on each patent
0 granted
4 published
Cytopia Pty Ltd a subsidiary
AU, as the owner printed on each patent
1 granted
2 published
YM Biosciences Australia Pty Ltd a subsidiary
named as the applicant on its applications, in AU. 2 more under the same name are not counted (printed in US)
0 granted
3 published
Calla Holdings, LLC a subsidiary
US, as the owner printed on each patent
1 granted
0 published
KITE PHARMA EU B.V. a subsidiary
named as the applicant on its applications, in NL
0 granted
1 published
KITE PHARMA EU B.V. a subsidiary
NL, as the owner printed on each patent
0 granted
1 published
MiroBio Limited a subsidiary
GB, as the owner printed on each patent
1 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 30, 202512,509,466Methods and compounds for treating paramyxoviridae virus infectionsOrganic fine chemistryGilead Sciences, Inc.
Dec 23, 202512,503,454LPA receptor antagonists and uses thereofPharmaceuticalsGilead Sciences, Inc.
Dec 16, 202512,497,408Tetracyclic compounds and methods for the treatment of Zika virus infectionOrganic fine chemistryGilead Sciences, Inc.
Dec 16, 202512,497,382GLP-1R modulating compoundsOrganic fine chemistryGilead Sciences, Inc.
Dec 9, 202512,492,189Solid forms of an HIV capsid inhibitorPharmaceuticalsGilead Sciences, Inc.
Dec 2, 202512,486,271Solid forms of a toll-like receptor modulatorPharmaceuticalsGilead Sciences, Inc.
Dec 2, 202512,486,252Solid forms of a Cot inhibitor compoundPharmaceuticalsGilead Sciences, Inc.
Nov 25, 202512,480,951Methods and compositions for T cell therapyAnalysis of biological materialsKite Pharma, Inc.
Nov 25, 202512,479,853HIV inhibitor compoundsOrganic fine chemistryGilead Sciences, Inc.
Nov 18, 2025D1,102,621Cassette rackKite Pharma, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388680CHIMERIC RECEPTORS AND METHODS OF USE THEREOFBiotechnologyKite Pharma, Inc.
Dec 25, 20252025/0388585PRMT5 INHIBITORS AND USES THEREOFPharmaceuticalsGilead Sciences, Inc.
Dec 18, 20252025/0382383TRICISTRONIC CONSTRUCTS FOR ANTI-GPC3 CARMedical technologyKite Pharma, Inc.
Dec 18, 20252025/0382278IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOFOrganic fine chemistryGilead Sciences, Inc.
Dec 11, 20252025/0376484PRMT5 INHIBITORS AND USES THEREOFPharmaceuticalsGilead Sciences, Inc.
Dec 11, 20252025/0375531TREATMENT OF HR+/HER2- BREAST CANCER USING SACITUZUMAB GOVITECANPharmaceuticalsGilead Sciences, Inc.
Dec 11, 20252025/0375480Methods for Generating Engineered LymphocytesBiotechnologyKite Pharma, Inc.
Dec 4, 20252025/0367386MEDICAL INJECTIONS AND RELATED DEVICES AND METHODSPharmaceuticalsGilead Sciences, Inc.
Dec 4, 20252025/0367385MEDICAL INJECTIONS AND RELATED DEVICES AND METHODSMedical technologyGilead Sciences, Inc.
Dec 4, 20252025/0367384MEDICAL INJECTIONS AND RELATED DEVICES AND METHODSMedical technologyGilead Sciences, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 127 · Organic fine chemistry 83 · Biotechnology 32 · Medical technology 20 · Analysis of biological materials 2 · Handling 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton GILD · research, not advice